SE0001438D0 - New chemical compounds and their use in therapy - Google Patents

New chemical compounds and their use in therapy

Info

Publication number
SE0001438D0
SE0001438D0 SE0001438A SE0001438A SE0001438D0 SE 0001438 D0 SE0001438 D0 SE 0001438D0 SE 0001438 A SE0001438 A SE 0001438A SE 0001438 A SE0001438 A SE 0001438A SE 0001438 D0 SE0001438 D0 SE 0001438D0
Authority
SE
Sweden
Prior art keywords
carbon atoms
alkyl
groups
group
absent
Prior art date
Application number
SE0001438A
Other languages
English (en)
Inventor
Durk Dijkstra De Meidoorn
Bastiaan Johan Venhuis
Haakan Vilhelm Wikstroem
Original Assignee
Axon Chemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Chemicals Bv filed Critical Axon Chemicals Bv
Priority to SE0001438A priority Critical patent/SE0001438D0/sv
Publication of SE0001438D0 publication Critical patent/SE0001438D0/sv
Priority to JP2001576014A priority patent/JP4819280B2/ja
Priority to CZ20023455A priority patent/CZ20023455A3/cs
Priority to PCT/SE2001/000840 priority patent/WO2001078713A1/en
Priority to US10/258,014 priority patent/US6683087B2/en
Priority to HU0300543A priority patent/HU229794B1/hu
Priority to CA002406044A priority patent/CA2406044C/en
Priority to PL365113A priority patent/PL204661B1/pl
Priority to AU4898201A priority patent/AU4898201A/xx
Priority to EP01922208A priority patent/EP1274411B1/en
Priority to CNB018082858A priority patent/CN1234351C/zh
Priority to PT01922208T priority patent/PT1274411E/pt
Priority to AU2001248982A priority patent/AU2001248982B2/en
Priority to AT01922208T priority patent/ATE300290T1/de
Priority to ES01922208T priority patent/ES2244604T3/es
Priority to CNB2005101253198A priority patent/CN100383126C/zh
Priority to NZ521860A priority patent/NZ521860A/en
Priority to DK01922208T priority patent/DK1274411T3/da
Priority to SI200130409T priority patent/SI1274411T1/sl
Priority to DE60112269T priority patent/DE60112269T2/de
Priority to ZA200207919A priority patent/ZA200207919B/xx
Priority to US10/737,782 priority patent/US6998405B2/en
Priority to HK06108406A priority patent/HK1088009A1/xx
Priority to US11/790,465 priority patent/USRE42802E1/en
Priority to US12/945,057 priority patent/USRE43244E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
SE0001438A 2000-04-18 2000-04-18 New chemical compounds and their use in therapy SE0001438D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy
DE60112269T DE60112269T2 (de) 2000-04-18 2001-04-17 Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung
CNB018082858A CN1234351C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
AU2001248982A AU2001248982B2 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
PCT/SE2001/000840 WO2001078713A1 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US10/258,014 US6683087B2 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
HU0300543A HU229794B1 (hu) 2000-04-18 2001-04-17 Katekolamin prodrug fenil-etil-aminok és kondenzált gyûrûs származékaik, valamint ezek alkalmazása és ezeket tartalmazó gyógyszerkészítmények
CA002406044A CA2406044C (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
PL365113A PL204661B1 (pl) 2000-04-18 2001-04-17 Fenyloetyloaminy i odmiany skondensowanych układów pierścieniowych jako proleki katecholamin, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
AU4898201A AU4898201A (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
EP01922208A EP1274411B1 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
JP2001576014A JP4819280B2 (ja) 2000-04-18 2001-04-17 カテコールアミンのプロドラッグとしてのフェニルエチルアミンおよび縮合環のヴァリアント（ｖａｒｉａｎｔ）、ならびにその使用
PT01922208T PT1274411E (pt) 2000-04-18 2001-04-17 Feniletilaminas e variantes de aneis condensados como pro-farmacos de catecolaminas, e sua utilizacao
CZ20023455A CZ20023455A3 (cs) 2000-04-18 2001-04-17 Fenylethylaminy a jejich varianty s anelovanými kruhy jako proléčiva katecholaminů a jejich použití
AT01922208T ATE300290T1 (de) 2000-04-18 2001-04-17 Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung
ES01922208T ES2244604T3 (es) 2000-04-18 2001-04-17 Feniletilaminas y variantes de anillos condensados como profarmacos de catecolaminas y su uso.
CNB2005101253198A CN100383126C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
NZ521860A NZ521860A (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as drugs of catecholamines, preparation process and their use
DK01922208T DK1274411T3 (da) 2000-04-18 2001-04-17 Phenylethylaminer og ringkondenserede varianter som prodrugs af catecholaminer og deres anvendelse
SI200130409T SI1274411T1 (sl) 2000-04-18 2001-04-17 Feniletilamini in variante s kondenziranimi obroci kot predzdravila kateholaminov in njihova uporaba
ZA200207919A ZA200207919B (en) 2000-04-18 2002-10-02 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use.
US10/737,782 US6998405B2 (en) 2000-04-18 2003-12-18 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
HK06108406A HK1088009A1 (en) 2000-04-18 2006-07-28 Phenylethylamines and condensend rings variants asprodrugs of catecholamines and their use
US11/790,465 USRE42802E1 (en) 2000-04-18 2007-04-25 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US12/945,057 USRE43244E1 (en) 2000-04-18 2010-11-12 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy

Publications (1)

Publication Number Publication Date
SE0001438D0 true SE0001438D0 (sv) 2000-04-18

Family

ID=20279367

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy

Country Status (20)

Country Link
US (4) US6683087B2 (sv)
EP (1) EP1274411B1 (sv)
JP (1) JP4819280B2 (sv)
CN (2) CN100383126C (sv)
AT (1) ATE300290T1 (sv)
AU (2) AU4898201A (sv)
CA (1) CA2406044C (sv)
CZ (1) CZ20023455A3 (sv)
DE (1) DE60112269T2 (sv)
DK (1) DK1274411T3 (sv)
ES (1) ES2244604T3 (sv)
HK (1) HK1088009A1 (sv)
HU (1) HU229794B1 (sv)
NZ (1) NZ521860A (sv)
PL (1) PL204661B1 (sv)
PT (1) PT1274411E (sv)
SE (1) SE0001438D0 (sv)
SI (1) SI1274411T1 (sv)
WO (1) WO2001078713A1 (sv)
ZA (1) ZA200207919B (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910623B2 (en) * 2005-07-22 2011-03-22 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
CA2616028A1 (en) * 2005-07-22 2007-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
EP2301934A1 (en) 2005-07-26 2011-03-30 BIAL - Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
DK2124947T3 (da) 2007-01-31 2017-11-06 Bial - Portela & Ca S A Doseringsskema for comt-inhibitorer
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
CA2718772C (en) 2008-03-17 2017-05-02 David Alexander Learmonth Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
CN102648284B (zh) * 2009-09-18 2014-09-24 株式会社里维松 多酚衍生物及其制造方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
RS59666B1 (sr) 2011-12-13 2020-01-31 BIAL PORTELA & Cª S A Hemijsko jedinjenje korisno kao intermedijer za pripremu inhibitora katehol-o-metiltransferaze
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EA202090987A8 (ru) 2017-11-24 2020-09-29 Х. Лундбекк А/С Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP2022533914A (ja) 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
US20220220077A1 (en) 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2022106352A1 (en) 2020-11-17 2022-05-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2023208865A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2023208869A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1179954A (fr) * 1956-02-11 1959-05-29 Rhone Poulenc Sa -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
GB1593888A (en) 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
ZA805648B (en) * 1979-09-14 1982-04-28 Sandoz Ltd Tetraline derivatives, their production and pharmaceutical compositions containing them
EP0026848B1 (de) 1979-09-14 1983-05-04 Sandoz Ag Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten
EP0077754B1 (en) * 1981-10-16 1990-09-26 Sandoz Ag Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives
AU6072090A (en) * 1989-07-05 1991-02-06 Whitby Research, Inc. Substituted 2-aminotetralins
KR100196888B1 (ko) 1991-04-17 1999-06-15 파마시아 앤드 업죤 컴패니 중추 작용성을 갖는 신규한 치환된 페닐아자사이클로 알칸
DE4114325A1 (de) 1991-05-02 1992-11-05 Sandoz Ag Octahydrobenzo(g)chinolin, seine herstellung und verwendung
GB2260980A (en) * 1991-10-31 1993-05-05 Shell Int Research Preparation of unsaturated cyclic ketones
GB9326010D0 (en) * 1993-12-21 1994-02-23 Sandoz Ltd Improvements in or relating to organic compounds
WO1999007667A1 (fr) * 1997-08-07 1999-02-18 Fujimoto Brothers Co., Ltd. Nouveaux derives d'ethylamine
WO2000006536A1 (en) * 1998-07-28 2000-02-10 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones
SV2001000202A (es) * 1999-10-20 2001-10-16 Warner Lambert Co Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson

Also Published As

Publication number Publication date
CN1781910A (zh) 2006-06-07
AU2001248982B2 (en) 2005-12-15
USRE42802E1 (en) 2011-10-04
US6683087B2 (en) 2004-01-27
CA2406044C (en) 2009-10-27
PL365113A1 (en) 2004-12-27
ZA200207919B (en) 2003-10-02
CN1234351C (zh) 2006-01-04
HK1088009A1 (en) 2006-10-27
US6998405B2 (en) 2006-02-14
US20030087948A1 (en) 2003-05-08
CN100383126C (zh) 2008-04-23
SI1274411T1 (sl) 2005-12-31
USRE43244E1 (en) 2012-03-13
CN1450894A (zh) 2003-10-22
EP1274411B1 (en) 2005-07-27
CA2406044A1 (en) 2001-10-25
DE60112269D1 (de) 2005-09-01
AU4898201A (en) 2001-10-30
US20040138281A1 (en) 2004-07-15
PL204661B1 (pl) 2010-01-29
CZ20023455A3 (cs) 2003-04-16
NZ521860A (en) 2004-03-26
ES2244604T3 (es) 2005-12-16
ATE300290T1 (de) 2005-08-15
HUP0300543A3 (en) 2009-04-28
DE60112269T2 (de) 2006-05-24
EP1274411A1 (en) 2003-01-15
HUP0300543A2 (hu) 2003-07-28
JP4819280B2 (ja) 2011-11-24
DK1274411T3 (da) 2005-11-14
JP2004500426A (ja) 2004-01-08
PT1274411E (pt) 2005-11-30
WO2001078713A1 (en) 2001-10-25
HU229794B1 (hu) 2014-07-28

Similar Documents

Publication Publication Date Title
SE0001438D0 (sv) New chemical compounds and their use in therapy
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
WO2003064404A1 (fr) Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant
ATE313535T1 (de) Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
HK1084024A1 (en) Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
HK1065785A1 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
JP2006507220A5 (sv)
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
GEP20053459B (en) New Thiadiazoles and Oxidiazoles and Their Use as Phosphodiesterase-7 Inhibitors
WO2004089308A3 (en) Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
TW200811100A (en) Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
KR970706826A (ko) 포스포디에스테라제 IV 억제제로서의 디아제피노-인돌(Diazepino-Indoles as Phosphodiesterase Ⅳ Inhibitors)
RU2380369C9 (ru) Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
JP2004502773A5 (sv)
JP2010505759A5 (sv)
NZ519126A (en) Novel IL-8 receptor antagonists
JP4030578B2 (ja) 新規の抗痙攣作用を有する４位に二置換アミン基を有する１−アリール（アラルキル）−イミダゾリン−２−オンおよびその製法
NZ520155A (en) Thienopyridine derivatives, their production and use
PT96536A (pt) Processo para a preparacao duma composicao fungicida contendo esteres de acido 2-{6-(pirimidinil)-indol-1-il}-acrilico substituidos e de produtos intermediarios
RU2003112454A (ru) Феноксифенилалкансульфонаты
HUP0302620A2 (hu) Új cukorbetegség-ellenes kombinációs gyógyszerkészítmények és eljárás ezek előállítására
DE60316849D1 (de) Verfahren zur herstellung von topotecan aus 10-hydroxy-4-(s) camtothecin
WO1998049165B1 (en) CYTOTOXIC COMPOUNDS: DERIVATIVES OF THE PYRIDO[2,3,4-kl] ACRIDINE RING SYSTEM
Yu et al. TARGET SYNTHESIS OF NOVEL PHARMACOLOGICAL ACTIVE MONO-AND BICYCLIC PIPERIDINES